Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.

Inga-Marie SchaeferMeijun Z LundbergElizabeth G DemiccoJoanna PrzybylMagdalena MatusiakFrédéric ChibonDavis R IngramJason L HornickWei-Lien WangSebastian BauerLaurence H BakerAlexander J LazarMatt van de RijnAdrian Mariño-EnríquezJonathan A Fletcher

Published in: Cancer (2021)

These studies show that nearly all np-LMS have TP53 and/or RB1 aberrations. Therefore, therapies targeting cell cycle and DNA damage checkpoint vulnerabilities should be prioritized for evaluations in LMS.

Keyphrases

cell cycle
dna damage
cell proliferation
dna repair
oxidative stress
copy number
cancer therapy
case control
gene expression
drug delivery